Biorg Med Chem 13:1116 Kumar A, Sharma P, Arun A, Meena LS (2022) Development of peptide vaccine candidate using highly antigenic PE-PGRS family proteins to stimulate the host immune response against Mycobacterium tuberculosis H37Rv: an immuno-informatics approach
7.3 2.9 ng/ml)
The study must be approved by an independent ethics committee, and every participant must give informed consent meaning they've received clear, honest information about what the study involves, what the risks are, and that they're free to withdraw at any time
Executive Vice President & President, Lilly Cardiometabolic Health, Eli Lilly and Company Why this matters 1 Triple agonist = next-gen metabolic therapy Mimics GLP-1, GIP, and glucagon multi-pathway metabolic control 2 Diabetes + obesity convergence Simultaneous A1C + weight control = major unmet need solved 3 Competitive landscape shift Raises the bar vs GLP-1 mono & dual incretin therapies 4 No plateau signal is critical Suggests longer-term sustained efficacy Safety profile (expected class effects) Nausea, diarrhea, vomiting (dose-escalation phase) Discontinuation rates relatively low (25%) My takeaway 1 Metabolic disease treatment is entering multi-hormone era 2 Obesity + diabetes becoming one therapeutic category 3 Efficacy approaching bariatric-level outcomes 4 Sets new benchmark for Novo Nordisk and competitors Bottom line: Retatrutide isnt just competing Its redefining how we treat metabolic disease at the systems level #Diabetes #Obesity #GLP1 #Biotech #ClinicalTrials #Pharma #Innovation To view or add a comment, sign in 2,706 followers
Hypogonadism in patients with sickle cell disease: central or peripheral
Mothers can begin treatment as soon as their physician confirms they are appropriate candidates based on BMI and health status
